America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What is the mechanism of action of AOH1996 and how does it differentiate from traditional chemotherapy?
**Interview with Dr. Linda Malkas on AOH1996 and Targeted Cancer Treatment**
**Interviewer:** Good afternoon, Dr. Malkas. Thank you for joining us today to discuss your team’s groundbreaking research on AOH1996, a new drug developed for targeted chemotherapy. Can you explain to our audience what exactly AOH1996 is and how it works?
**Dr. Malkas:** Thank you for having me. AOH1996 is an innovative therapeutic molecule that we’re exploring for its potential to selectively target and kill cancer cells. It specifically targets a mutated variant of a protein known as PCNA, which plays a crucial role in DNA replication and tumor growth. Think of PCNA as a busy airline terminal; AOH1996 acts as a blizzard that can effectively shut down operations, halting the flow of cancer cells.
**Interviewer:** That’s a fascinating analogy! Over the past two decades, how has AOH1996 been developed, and what types of cancers have shown responsiveness in your studies?
**Dr. Malkas:** Our research has involved extensive preclinical testing over a span of nearly twenty years. In our studies published in *Cell Chemical Biology*, we tested AOH1996 on more than 70 different cancer cell lines, including those associated with breast, prostate, brain, ovarian, cervical, skin, and lung cancers. The drug has shown promise in selectively disrupting the normal reproductive cycle of cancer cells, which helps in selectively killing them while sparing healthy cells.
**Interviewer:** Impressive! What are the next steps for AOH1996 after these promising preclinical results?
**Dr. Malkas:** The next critical phase involves advancing our findings to human clinical trials. These trials will help us assess the safety and efficacy of AOH1996 in humans, which is an essential step for any new treatment.
**Interviewer:** Many patients are eager for new treatment options. How do you think AOH1996 compares to conventional therapies currently available?
**Dr. Malkas:** AOH1996 offers a more targeted approach, which can potentially lead to fewer side effects compared to traditional chemotherapy. By focusing specifically on the cancer variant of PCNA, we hope to improve treatment outcomes without impacting normal cells as severely as conventional therapies do.
**Interviewer:** As a leader in cancer research at City of Hope, what message do you have for patients currently battling cancer?
**Dr. Malkas:** I want to assure patients that transformative advancements are being made in cancer treatment. Our ongoing research efforts aim to provide more effective and less toxic treatment options. I encourage patients to stay hopeful and engaged with their healthcare providers about the latest therapies and clinical trials available.
**Interviewer:** Thank you, Dr. Malkas, for your insights into this exciting development in cancer treatment. We look forward to seeing the results of your upcoming clinical trials.
**Dr. Malkas:** Thank you for having me. It’s important to keep the conversation going about innovative cancer therapies, and I’m grateful for the opportunity to share our work.
